Talimogene and Atezolizumab Trial in HER2-Negative Breast Cancer
In a remarkable stride toward advancing cancer immunotherapy, a recent phase II clinical trial has illuminated the promising synergy between talimogene laherparepvec (T-VEC) and atezolizumab...
















